A Phase 3 interventional study of Ertugliflozin 5 mg and Ertugliflozin 10 mg in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-02.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 — 3 open to participants now, 3 under way, none of them phase 3. ertugliflozin · Diabetes Mellitus, Type 2.
Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, this one is the 2nd largest by enrollment, is one of 6 that started in 2013, is one of 11 in phase 3, and was the 11th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Amsterdam UMC, location VUmc · Sites in United States, Netherlands
Ages 18–85
Baylor Research Institute · Sites in United States
Ages 18–84
Shanghai Zhongshan Hospital · Sites in China
Ages 19+
By country, each count listing its studies:
ertugliflozin: first FDA approval 2017 (STEGLATRO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 6 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,326 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 83 across the 28 interventional studies. Of the 24 that completed or were terminated, 19 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 28 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 7th largest by enrollment of the 170 interventional ones that give a count, is one of 13 that started in 2013, is one of 86 in phase 3, and was the 155th registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of the addition of ertugliflozin (MK-8835/PF-04971729) compared with the addition of glimepiride in participants with T2DM who have inadequate glycemic control on metformin. The primary hypothesis of this study is that after 52 weeks, the change from baseline in hemoglobin A1c (A1C) in participants treated with the addition of ertugliflozin 15 mg once daily is non-inferior compared with that in participants treated with the addition of glimepiride.
The duration of the trial will be up to approximately 122 weeks. This will include a 1-week screening period, an up to 13-week wash-off/titration/dose stabilization period, a 2-week placebo run-in period, a 104-week double-blind, active comparator-controlled treatment period, and a post-treatment telephone contact 14 days after the last dose of study drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ertugliflozin 5 mg once daily (QD) from Day 1 to Week 104
Drug: Ertugliflozin 5 mg · Drug: Placebo to Ertugliflozin · Drug: Placebo to Glimepiride · Drug: Metformin · Drug: Sitagliptin
Ertugliflozin 15 mg QD from Day 1 to Week 104
Drug: Ertugliflozin 5 mg · Drug: Ertugliflozin 10 mg · Drug: Placebo to Glimepiride · Drug: Metformin · Drug: Sitagliptin
Glimepiride to a maximum of 8 mg QD from Day 1 to Week 104
Drug: Glimerpiride · Drug: Placebo to Ertugliflozin · Drug: Metformin · Drug: Sitagliptin
Ertugliflozin, 5 mg, oral, once daily, from Day 1 to Week 104
Also known as: MK-8835
Ertugliflozin, 10 mg, oral, once daily from Day 1 to Week 104.
Also known as: MK-8355
Glimepiride, oral tablets, initiated at 1 mg daily and titrated up to the maximum approved dose (8 mg daily based on the local country label) or maximum tolerated dose
Matching placebo to ertugliflozin, 5 mg and/or 10 mg, oral, once daily, from Day 1 to Week 104
Matching placebo to glimepiride, 1 mg or 2 mg, oral, once daily, from Day 1 to Week 104.
Participants are to remain on their stable doses of metformin (oral, \>=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin \<1500 at screening are up-titrated to \>= 1500 daily.
Open label, oral, once daily, rescue medication as required.
Change From Baseline in Hemoglobin A1C (A1C) at Week 52: Excluding Rescue Approach
A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 52 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication. The primary study objective was the MK-8835 15 mg vs. glimepiride comparison; the MK-8835 5mg vs glimerpiride comparison was a secondary study objective.
Time frame: Baseline and Week 52
Percentage of Participants Experiencing An Adverse Event (AE) Up to Week 106
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
Time frame: Up to Week 106
Percentage of Participants Discontinuing Study Treatment Due to an AE Up to Week 104
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
Time frame: Up to Week 104
Percentage of Participants With an Adverse Event of Symptomatic Hypoglycemia Up to Week 52: Excluding Rescue Approach
Symptomatic hypoglycemia was an event with clinical symptoms reported by the investigator as hypoglycemia (biochemical documentation not required). Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication.
Time frame: Up to Week 52
Change From Baseline in Body Weight at Week 52 Excluding Rescue Approach
This change from baseline reflects the Week 52 body weight minus the Week 0 body weight. Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication.
Time frame: Baseline and Week 52
Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 52 Excluding Rescue Approach
This change from baseline reflects the Week 52 SBP minus the Week 0 SBP. Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication.
Time frame: Baseline and Week 52
The trial was conducted in 16 countries at 232 trial centers in Argentina, Canada, Czech Republic, Hungary, South Korea, Lithuania, Mexico, Philippines, Poland, Romania, Russia, Slovakia, South Africa, Taiwan, Ukraine, and the United States.
| Milestone | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Glimepiride |
|---|---|---|---|
| Started | 448 | 441 | 437 |
| Treated | 448 | 440 | 437 |
| Site issue | 445 | 435 | 435 |
| Completed | 339 | 340 | 327 |
| Not completed | 109 | 101 | 110 |
| Withdrew: Hyperglycemia | 18 | 17 | 17 |
| Withdrew: Lack of efficacy | 1 | 0 | 1 |
| Withdrew: Lost to follow-up | 22 | 17 | 18 |
| Withdrew: Non-compliance with study drug | 6 | 4 | 1 |
| Withdrew: Physician decision | 1 | 4 | 6 |
| Withdrew: Protocol violation | 4 | 5 | 4 |
| Withdrew: Screen failure | 0 | 1 | 0 |
| Withdrew: Study terminated by sponsor | 7 | 5 | 12 |
| Withdrew: Participant moves | 2 | 5 | 3 |
| Withdrew: Withdrawal by subject | 28 | 29 | 34 |
| Withdrew: Creatinine/egfr | 0 | 0 | 1 |
| Withdrew: Death | 7 | 1 | 2 |
| Withdrew: Excluded medication | 1 | 1 | 2 |
| Withdrew: Adverse event | 9 | 7 | 7 |
| Withdrew: Treated but excluded at 1 trial site | 3 | 5 | 2 |
A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). A1C represents the percentage of glycated hemoglobin. This change from baseline reflects the Week 52 A1C minus the Week 0 A1C. A negative number indicates a reduction in A1C level. Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication. The primary study objective was the MK-8835 15 mg vs. glimepiride comparison; the MK-8835 5mg vs glimerpiride comparison was a secondary study objective.
| Percent | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Glimepiride |
|---|---|---|---|
| Change From Baseline in Hemoglobin A1C (A1C) at Week 52: Excluding Rescue Approach | -0.56 (-0.65 to -0.47) | -0.64 (-0.73 to -0.55) | -0.74 (-0.83 to -0.65) |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
| Percentage of Participants | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Glimepiride |
|---|---|---|---|
| Percentage of Participants Experiencing An Adverse Event (AE) Up to Week 106 | 70.1 | 71.3 | 69.7 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
| Percentage of Participants | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Glimepiride |
|---|---|---|---|
| Percentage of Participants Discontinuing Study Treatment Due to an AE Up to Week 104 | 6.5 | 8.0 | 5.1 |
Symptomatic hypoglycemia was an event with clinical symptoms reported by the investigator as hypoglycemia (biochemical documentation not required). Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication.
| Percentage of Participants | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Glimepiride |
|---|---|---|---|
| Percentage of Participants With an Adverse Event of Symptomatic Hypoglycemia Up to Week 52: Excluding Rescue Approach | 3.1 | 5.2 | 19.2 |
This change from baseline reflects the Week 52 body weight minus the Week 0 body weight. Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication.
| Kilograms | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Glimepiride |
|---|---|---|---|
| Change From Baseline in Body Weight at Week 52 Excluding Rescue Approach | -2.96 (-3.31 to -2.61) | -3.38 (-3.73 to -3.03) | 0.91 (0.56 to 1.25) |
This change from baseline reflects the Week 52 SBP minus the Week 0 SBP. Participants who met glycemic rescue criteria received open-label sitagliptin glycemic rescue medication.
| mmHg | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Glimepiride |
|---|---|---|---|
| Change From Baseline in Sitting Systolic Blood Pressure (SBP) at Week 52 Excluding Rescue Approach | -2.25 (-3.36 to -1.13) | -3.81 (-4.91 to -2.71) | 0.95 (-0.15 to 2.06) |
Collected over Up to Week 106. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ertugliflozin 5 mg | 7/445 (1.6%) | 41/445 (9.2%) | 110/445 (24.7%) |
| Ertugliflozin 15 mg | 2/435 (0.5%) | 32/435 (7.4%) | 104/435 (23.9%) |
| Glimepiride | 1/435 (0.2%) | 30/435 (6.9%) | 165/435 (37.9%) |
| Event | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Glimepiride |
|---|---|---|---|
| Angina unstableCardiac disorders | 2/445 | 0/435 | 2/435 |
| Chronic calculous cholecystitisHepatobiliary disorders | 0/445 | 2/435 | 0/435 |
| Breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/445 | 2/435 | 0/435 |
| Coronary artery diseaseCardiac disorders | 2/445 | 0/435 | 0/435 |
| Lobar pneumoniaInfections and infestations | 2/445 | 0/435 | 0/435 |
| StrokeNervous system disorders | 2/445 | 0/435 | 0/435 |
| Acute coronary syndromeCardiac disorders | 1/445 | 1/435 | 0/435 |
| Acute myocardial infarctionCardiac disorders | 1/445 | 1/435 | 0/435 |
| Cardiac failureCardiac disorders | 1/445 | 1/435 | 0/435 |
| Myocardial infarctionCardiac disorders | 0/445 | 1/435 | 0/435 |
| Event | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Glimepiride |
|---|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 14/445 | 25/435 | 82/435 |
| Urinary tract infectionInfections and infestations | 27/445 | 28/435 | 29/435 |
| Asymptomatic hypoglycaemiaMetabolism and nutrition disorders | 7/445 | 4/435 | 27/435 |
| Upper respiratory tract infectionInfections and infestations | 27/445 | 14/435 | 18/435 |
| HeadacheNervous system disorders | 25/445 | 19/435 | 19/435 |
| Common coldInfections and infestations | 21/445 | 17/435 | 23/435 |
| DiarrhoeaGastrointestinal disorders | 13/445 | 12/435 | 22/435 |
All randomized participants
| Age, Continuous(Years) | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Glimepiride | Total |
|---|---|---|---|---|
| Mean | 58.8 ± 9.7 | 58.0 ± 9.9 | 57.8 ± 9.2 | 58.2 ± 9.6 |
| Sex: Female, Male(Participants) | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Glimepiride | Total |
|---|---|---|---|---|
| Female | 221 | 250 | 213 | 684 |
| Male | 227 | 191 | 224 | 642 |
| Race (NIH/OMB)(Participants) | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Glimepiride | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 5 | 3 | 5 | 13 |
| Asian | 81 | 86 | 73 | 240 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 17 | 19 | 25 | 61 |
| White | 332 | 316 | 318 | 966 |
| More than one race | 13 | 17 | 16 | 46 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Body Weight(Kilograms) | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Glimepiride | Total |
|---|---|---|---|---|
| Mean | 87.9 ± 18.9 | 85.6 ± 19.1 | 86.8 ± 20.7 | 86.8 ± 19.6 |
| Hemoglobin A1C(Percentage) | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Glimepiride | Total |
|---|---|---|---|---|
| Mean | 7.81 ± 0.60 | 7.80 ± 0.60 | 7.76 ± 0.60 | 7.79 ± 0.60 |
| Sitting Systolic Blood Pressure(Millimeters of mercury) | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Glimepiride | Total |
|---|---|---|---|---|
| Mean | 130.2 ± 12.8 | 130.8 ± 12.4 | 129.9 ± 12.0 | 130.3 ± 12.4 |
| Prior Antihyperglycemic (AHA) Medication (Monotherapy or Dual Therapy)(Participants) | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Glimepiride | Total |
|---|---|---|---|---|
| Prior Antihyperglycemic Medication | 448 | 439 | 437 | 1324 |
| No Prior Use & Not on Antihyperglycemic Medication | 0 | 1 | 0 | 1 |
| Data not available | 0 | 1 | 0 | 1 |
| Estimated Glomerular Filtration Rate (eGFR)(milliliters/minute/1.73 meters^2) | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Glimepiride | Total |
|---|---|---|---|---|
| Mean | 88.3 ± 18.7 | 86.7 ± 18.3 | 86.6 ± 18.5 | 87.2 ± 18.5 |
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Dec 2013 to primary completion in Apr 2017, 40 months.
Results were first posted in May 2018, 1 year after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 40 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ertugliflozin